Abstract: SA-PO268

The Cure Glomerulonephropathy (CureGN) IgA Nephropathy and IgA Vasculitis Pediatric Cohort

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Selewski, David T., University of Michigan, Ann Arbor, Michigan, United States
  • Iragorri, Sandra, None, Cleveland, Ohio, United States
  • Khalid, Myda, Indiana University, Indianapolis, Indiana, United States
  • Liapis, Helen, Arkana Laboratories, Munich, Germany
  • Lugani, Francesca, G.Gaslini Children''s Hospital, Genova, Italy
  • Mason, Sherene, Connecticut Children's Medical Center, Hartford, Connecticut, United States
  • Nester, Carla M., University of Iowa, Iowa City, Iowa, United States
  • Noone, Damien Gerard, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Rheault, Michelle N., University of Minnesota, Minneapolis, Minnesota, United States
  • Sreedharan, Rajasree, Medical College of Wisconsin, Wauwatosa, Wisconsin, United States
  • Srivastava, Tarak, Childrens's Mercy Hospital, Kansas City, Missouri, United States
  • Bou Matar, Raed, None, Cleveland, Ohio, United States
  • Swiatecka-Urban, Agnieszka, Children's Hospital of Pittsburgh of UMPC, Pittsburgh, Pennsylvania, United States
  • Twombley, Katherine, Medical University of South Carolina, Charleston, South Carolina, United States
  • Vasylyeva, Tetyana L., None, Cleveland, Ohio, United States
  • Weaver, Donald J., Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States
  • Yin, Hong, Childrens Health Care of Atlanta, Atlanta, Georgia, United States
  • Kiryluk, Krzysztof, Columbia University, New York, New York, United States
  • Cai, Yi, Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
  • Chishti, Aftab S., University of Kentucky , Lexington, Kentucky, United States
  • D'Agati, Vivette D., Columbia University College of Physicians and Surgeons, New York, New York, United States
  • D'Alessandri-Silva, Cynthia J., Connecticut Children's Medical Center, Hartford, Connecticut, United States
  • Gbadegesin, Rasheed A., Duke University Medical Center, Durham, North Carolina, United States
  • Gipson, Debbie S., University of Michigan, Ann Arbor, Michigan, United States
  • Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Group or Team Name

  • On behalf of the CureGN IgA writing group
Background

Cure Glomerulonephropathy (CureGN) is a multi-center(66 sites), NIDDK-funded longitudinal observational cohort study of 2400 prevalent (biopsy within 5 years) patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy (IgAN), including IgA vasculitis (IgAV, previously referred to as Henoch-Schonlein Purpura). The IgAN/IgAV cohort has recently filled and we present the enrollment data for pediatric IgAN and IgAV.

Methods

Data for all pediatric patients (<18 years) with biopsy confirmed IgAN or IgAV were reviewed. This analysis compares those with IgAN and IgAV. Data (lab, treatment) up to the time of enrollment are shown using descriptive statistics and univariate tests with results as median(IQR) or N(%).

Results

590 patients are enrolled in the IgAN/IgAV cohort including 235 pediatric patients (143 (61%) IgAN and 92 (39%) IgAV). A comparison of IgAN and IgAV is presented in Table 1. Those with IgAV differed significantly in age at diagnosis, disease duration, proteinuria at biopsy, and serum albumin at biopsy. Those with IgAV were significantly more likely than those with IgAN to receive immunosuppression and corticosteroids (Table 1).

Conclusion

This study reveals significant differences in the demographics, disease presentation and treatments in children with IgAV and IgAN. Participants will now be followed longitudinally as part of CureGN to further define disease characteristics such as disease progression, pathophysiology and response to therapy.

Table 1: Comparison of Pediatric IgAV and IgAN

Funding

  • NIDDK Support